Anticoagulation for atrial fibrillation (AFib) is generally recommended when your stroke risk, measured by a scoring system called CHA2DS2-VASc, reaches 2 or higher for men and 3 or higher for women. At a score of 1 for men (or 2 for women), anticoagulation is reasonable but involves more of a shared decision between you and your doctor. A score of 0 for men or 1 for women (where the only point comes from being female) typically means the stroke risk is low enough that blood thinners aren’t needed.
How Your Stroke Risk Score Works
The CHA2DS2-VASc score adds up points based on conditions that independently raise your chance of having a stroke while in AFib. Each of these factors earns 1 point: heart failure, high blood pressure, diabetes, vascular disease (such as a prior heart attack or peripheral artery disease), age 65 to 74, and female sex. Two factors are weighted more heavily at 2 points each: age 75 or older, and a history of stroke or transient ischemic attack (TIA). The maximum possible score is 9.
The higher your score, the greater your annual stroke risk. At a score of 0, the yearly risk is under 1%. By the time you reach a score of 2, that risk climbs to roughly 2% to 3% per year, and it continues to rise with each additional point. These numbers matter because AFib-related strokes tend to be more severe and more disabling than strokes from other causes, so the threshold for preventive treatment is relatively low.
The 2023 guidelines from the American College of Cardiology and American Heart Association use this score as the primary tool for deciding about blood thinners. Female sex earns a point, but if it’s your only risk factor, that alone doesn’t warrant treatment. This is why the practical thresholds differ by sex: women need one additional clinical risk factor beyond their sex to reach the decision point.
Bleeding Risk: What the HAS-BLED Score Does
Before starting a blood thinner, your doctor will also assess your bleeding risk using a tool called HAS-BLED. It accounts for high blood pressure, abnormal kidney or liver function, prior stroke, a history of bleeding, unstable blood-thinning levels (if on warfarin), age 65 or older, and regular use of drugs or alcohol that increase bleeding. A score of 3 or higher signals high bleeding risk.
A high HAS-BLED score does not mean you shouldn’t take a blood thinner. This is a common misconception. The score exists to flag modifiable risk factors, like uncontrolled blood pressure or alcohol use, that can be addressed to make anticoagulation safer. In most cases, the stroke risk from untreated AFib outweighs the bleeding risk, even in higher-risk patients. The goal is to fix what’s fixable, not to avoid treatment.
Paroxysmal AFib Carries Real Risk
If your AFib comes and goes (paroxysmal AFib, meaning episodes that resolve on their own within seven days), you might assume you only need blood thinners during episodes. That’s not how it works. Stroke risk is based on your CHA2DS2-VASc score, not on whether your AFib is intermittent, persistent, or permanent.
Paroxysmal AFib does carry a somewhat lower stroke rate than persistent or permanent AFib. In one large analysis of patients not on blood thinners, yearly stroke rates were 2.1% for paroxysmal, 3.0% for persistent, and 4.2% for permanent AFib. But these rates are all high enough to justify treatment. Current guidelines recommend that people with paroxysmal AFib receive the same anticoagulation as those with persistent or permanent AFib, based on their risk score. Continuous anticoagulation is the standard, not on-and-off treatment timed to episodes.
Device-Detected AFib: The 24-Hour Threshold
Pacemakers, implantable monitors, and some smartwatches can detect brief, asymptomatic episodes of AFib that you’d never feel. The question of when these episodes warrant blood thinners is still evolving, but a key study (ASSERT) found that episodes lasting more than 24 hours were associated with a significantly increased stroke risk, roughly tripling the hazard compared to patients without detected episodes. Episodes shorter than 24 hours did not show a statistically significant increase in stroke risk.
This doesn’t mean short episodes are harmless, but it does suggest that very brief runs of AFib detected by a device may not automatically require anticoagulation. If your device picks up episodes, the duration and your underlying risk factors both matter in the decision.
DOACs vs. Warfarin
For most people with AFib, newer blood thinners called direct oral anticoagulants (DOACs) are now preferred over warfarin. Compared to warfarin, DOACs reduce the risk of stroke by about 13%, cut the risk of bleeding inside the skull by 36%, and lower the rate of major bleeding by 15%. They also don’t require regular blood tests or the dietary restrictions that come with warfarin.
There are two important exceptions. If you have a mechanical heart valve, warfarin is the only safe option. DOACs have been tested in this group and caused harm. The same applies to moderate or severe rheumatic mitral stenosis, a condition where the mitral valve has been damaged by rheumatic fever. For virtually all other forms of heart valve disease, including bioprosthetic valves and common conditions like aortic stenosis or mitral regurgitation, DOACs are recommended over warfarin. European cardiology guidelines have suggested dropping the old “valvular vs. nonvalvular” terminology altogether, since it caused confusion about who could safely take DOACs.
Anticoagulation Around Cardioversion
If you’re scheduled for cardioversion (a procedure to restore normal heart rhythm), anticoagulation follows a specific timeline. When AFib has lasted more than 48 hours or the duration is unknown, guidelines call for at least 3 weeks of blood thinners before the procedure. After cardioversion, you’ll need a minimum of 4 weeks of anticoagulation regardless of whether the procedure appears successful, because the heart’s upper chambers can remain sluggish and clot-prone even after rhythm is restored.
An alternative approach uses an imaging test called transesophageal echocardiography to check for clots in the heart before proceeding. If no clot is found, cardioversion can happen sooner, but the 4-week post-procedure anticoagulation requirement stays the same. After those 4 weeks, whether you continue long-term depends on your CHA2DS2-VASc score, not on whether your heart stayed in normal rhythm.
When Anticoagulation Can’t Be Used
There are situations where blood thinners are too dangerous to use. Active bleeding, a recent brain hemorrhage, major trauma, a serious clotting disorder, and recent major surgery are all absolute contraindications. Some situations are more of a gray area: a recent gastrointestinal bleed, a planned minor surgery, or certain blood vessel conditions like aortic aneurysm may require temporary interruption rather than permanent avoidance.
For people who clearly need stroke prevention but can’t tolerate long-term blood thinners, a procedure called left atrial appendage closure offers an alternative. This involves placing a small device to seal off the part of the heart where most AFib-related clots form. It doesn’t eliminate stroke risk as effectively as anticoagulation in the short term, but it removes the ongoing bleeding risk that comes with daily medication.